NZCR is at the forefront of early phase clinical research. Our focus on quality and innovation has resulted in many exciting medical breakthroughs. These news articles highlight current research projects and innovations at NZCR.
Home / About Us / About NZCR / News
New Zealand Clinical Research (NZCR) is a leading early-phase clinical research provider. Our expert research team has conducted over 750 clinical studies in NZ involving more than 15,000 New Zealanders. With facilities in Wellington, Hamilton, Christchurch, and Auckland, clinical trials are being conducted daily to test investigative medicines. For NZCR to do this research it needs healthy people and patients to join its research community.
NZCR, a top provider of clinical trials in NZ, was commissioned to run the world’s first ‘in-human’ trial of this Nobel prize winning technique.
NZCR's Professor Ed Gane is a world leading researcher. His recent research of Hepatitis B in Japanese and Non Japanese subjects has recently been published in Anti Viral Therapy
The life of a participant in clinical trials in NZ gives individuals the opportunity to take part in research that could improve many people's lives. Participating in a clinical trial in NZ can vary depending on the type of trial and its objectives, and medical trials can be from one day to up to 18 days with follow-up visits.
Clinical trials in NZ are designed to advance global health, and usually are part of a multi-country trial approach. At NZCR , our clinical research teams’ partner with leading medical researchers, doctors and science experts to help develop innovative medicines and treatments that improve people's lives.
NZCR Clinical Trial - Universe Study showing exciting results
Hope offered by new ALS research findings
NZCR and Verve Therapeutics - Gene Editing Study includes first patient in Auckland New Zealand.
Our research partner Alvotech has announced positive results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara® conducted at NZCR research facilities.
NZCR Lead Research Physician Dr Alexandra Cole, CEO Dr Christian Schwabe and Business Development Manager, Marcus Burrows are pleased to be representing NZCR at ARCS 2022 in Sydney this week.
New Zealand Clinical Research (NZCR) is putting put out a call for healthy males in Auckland and Christchurch to be part of two large trials researching potential new treatments for breast cancer.
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects
